| scholarly article | Q13442814 |
| P819 | ADS bibcode | 2019NatCo..10.1916A |
| P356 | DOI | 10.1038/S41467-019-09801-X |
| P932 | PMC publication ID | 6478874 |
| P698 | PubMed publication ID | 31015489 |
| P50 | author | Yogendra Kanthi | Q59149661 |
| Shanea K Estes | Q123337184 | ||
| P2093 | author name string | Jason S Knight | |
| He Meng | |||
| Jose A Diaz | |||
| David J Pinsky | |||
| Srilakshmi Yalavarthi | |||
| Alex A Gandhi | |||
| Paula L Bockenstedt | |||
| Joan M Greve | |||
| Andrew P Vreede | |||
| Olivia R Palmer | |||
| Ramadan A Ali | |||
| P2860 | cites work | High affinity binding of beta 2-glycoprotein I to human endothelial cells is mediated by annexin II | Q22254095 |
| Extracellular DNA traps promote thrombosis. | Q24613579 | ||
| Regulation of neutrophil function by adenosine | Q24620317 | ||
| Adenosine receptors: therapeutic aspects for inflammatory and immune diseases | Q24651475 | ||
| Treatment of catastrophic antiphospholipid syndrome with defibrotide, a proposed vascular endothelial cell modulator | Q28193764 | ||
| International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS) | Q28292418 | ||
| Investigations on beta 2-glycoprotein-I in the rat: isolation from serum and demonstration in lipoprotein density fractions | Q28575622 | ||
| Netting neutrophils in autoimmune small-vessel vasculitis | Q29615432 | ||
| Cyclic AMP-mediated suppression of neutrophil extracellular trap formation and apoptosis by the Bordetella pertussis adenylate cyclase toxin | Q30303150 | ||
| A novel pathway for human endothelial cell activation by antiphospholipid/anti-β2 glycoprotein I antibodies | Q30422807 | ||
| Activation of the A(3) adenosine receptor suppresses superoxide production and chemotaxis of mouse bone marrow neutrophils | Q30438821 | ||
| Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients | Q33341941 | ||
| The impact of gender on clinical manifestations of primary antiphospholipid syndrome | Q33368554 | ||
| Diagnosis and classification of the antiphospholipid syndrome | Q33412887 | ||
| The relevance of "non-criteria" clinical manifestations of antiphospholipid syndrome: 14th International Congress on Antiphospholipid Antibodies Technical Task Force Report on Antiphospholipid Syndrome Clinical Features | Q33420116 | ||
| Thrombosis, Microangiopathies, and Inflammation | Q33425213 | ||
| Thrombosis: tangled up in NETs | Q33556910 | ||
| The pathogenesis of the antiphospholipid syndrome | Q34332601 | ||
| 14th International Congress on Antiphospholipid Antibodies: task force report on antiphospholipid syndrome treatment trends | Q34400373 | ||
| Autophagy mediates the delivery of thrombogenic tissue factor to neutrophil extracellular traps in human sepsis | Q34429010 | ||
| Peptidylarginine deiminase inhibition disrupts NET formation and protects against kidney, skin and vascular disease in lupus-prone MRL/lpr mice | Q35060808 | ||
| Intact Toll-like receptor 9 signaling in neutrophils modulates normal thrombogenesis in mice | Q35813798 | ||
| Monocytes, neutrophils, and platelets cooperate to initiate and propagate venous thrombosis in mice in vivo. | Q35894194 | ||
| Compartmentalisation of phosphodiesterases and protein kinase A: opposites attract | Q36156003 | ||
| Adenosine: a physiological modulator of superoxide anion generation by human neutrophils. | Q36349017 | ||
| Neutrophil histone modification by peptidylarginine deiminase 4 is critical for deep vein thrombosis in mice. | Q36884300 | ||
| Peptidylarginine deiminase inhibition is immunomodulatory and vasculoprotective in murine lupus | Q36966870 | ||
| Rivaroxaban versus warfarin to treat patients with thrombotic antiphospholipid syndrome, with or without systemic lupus erythematosus (RAPS): a randomised, controlled, open-label, phase 2/3, non-inferiority trial | Q37230504 | ||
| Prostaglandin E2 inhibits neutrophil extracellular trap formation through production of cyclic AMP. | Q37686116 | ||
| Classical and pleiotropic actions of dipyridamole: Not enough light to illuminate the dark tunnel? | Q38214876 | ||
| Ubiquinol Effects on Antiphospholipid Syndrome Prothrombotic Profile: A Randomized, Placebo-Controlled Trial | Q38374450 | ||
| The Role of Reactive Oxygen Species (ROS) in the Formation of Extracellular Traps (ETs) in Humans. | Q38462105 | ||
| Antiphospholipid syndrome: an update for clinicians and scientists | Q38679842 | ||
| Global Prevalence of Spondyloarthritis: A Systematic Review and Meta-Regression Analysis | Q38682092 | ||
| Adenosine and adenosine receptors in the pathogenesis and treatment of rheumatic diseases | Q39004042 | ||
| Neutrophil Extracellular Traps in Atherosclerosis and Atherothrombosis | Q39139748 | ||
| In Vivo Role of Neutrophil Extracellular Traps in Antiphospholipid Antibody-Mediated Venous Thrombosis | Q39328138 | ||
| Beta2-glycoprotein I (beta2-GPI) mRNA is expressed by several cell types involved in anti-phospholipid syndrome-related tissue damage | Q40975353 | ||
| Purinoceptors and platelet aggregation | Q41456002 | ||
| Release of neutrophil extracellular traps by neutrophils stimulated with antiphospholipid antibodies: a newly identified mechanism of thrombosis in the antiphospholipid syndrome. | Q41818166 | ||
| Activated signature of antiphospholipid syndrome neutrophils reveals potential therapeutic target | Q42162703 | ||
| Secondary stroke prevention with low-dose aspirin, sustained release dipyridamole alone and in combination. ESPS Investigators. European Stroke Prevention Study | Q42538886 | ||
| Beta-2-glycoprotein I expression on monocytes is increased in anti-phospholipid antibody syndrome and correlates with tissue factor expression | Q44461543 | ||
| Characterization of monocyte tissue factor activity induced by IgG antiphospholipid antibodies and inhibition by dilazep | Q44958578 | ||
| Comparison of simultaneous measurement of mouse systolic arterial blood pressure by radiotelemetry and tail-cuff methods | Q47205852 | ||
| Is leukocyte tissue factor the key to venous thrombosis in antiphospholipid syndrome? | Q52884718 | ||
| Regadenoson pharmacokinetics and tolerability in subjects with impaired renal function. | Q53567783 | ||
| Adenosine 2A receptor is protective against renal injury in MRL/lpr mice. | Q54395725 | ||
| Degradation of neutrophil extracellular traps is decreased in patients with antiphospholipid syndrome. | Q54505081 | ||
| Ectonucleotidase-Mediated Suppression of Lupus Autoimmunity and Vascular Dysfunction. | Q55475388 | ||
| Antiphospholipid syndrome | Q55891386 | ||
| The anti-beta2-glycoprotein I activity in human anti-phospholipid syndrome sera is due to monoreactive low-affinity autoantibodies directed to epitopes located on native beta2-glycoprotein I and preserved during species' evolution | Q56903194 | ||
| Anti–β2-glycoprotein I antibodies induce monocyte release of tumor necrosis factor α and tissue factor by signal transduction pathways involving lipid rafts | Q59140753 | ||
| Prevention of perinatal consequences of pre-eclampsia with low-dose aspirin: results of the epreda trial. The Epreda Trial Study Group | Q67773954 | ||
| Protein kinase A downregulates the phosphorylation of p47 phox in human neutrophils: a possible pathway for inhibition of the respiratory burst | Q71617131 | ||
| Low-Density Granulocytes Are Increased in Antiphospholipid Syndrome and Are Associated With Anti-β2 -Glycoprotein I Antibodies: Comment on the Article by Yalavarthi et al | Q87046786 | ||
| Neutrophil extracellular traps promote thrombin generation through platelet-dependent and platelet-independent mechanisms | Q87381493 | ||
| Neutrophil extracellular trap release is associated with antinuclear antibodies in systemic lupus erythematosus and anti-phospholipid syndrome | Q88244848 | ||
| Anti-β2GPI/β2GPI induces neutrophil extracellular traps formation to promote thrombogenesis via the TLR4/MyD88/MAPKs axis activation | Q89043558 | ||
| Randomized phase 2 trial of regadenoson for treatment of acute vaso-occlusive crises in sickle cell disease | Q89777309 | ||
| Update on the electrolytic IVC model for pre-clinical studies of venous thrombosis | Q90480571 | ||
| Insights into the diagnosis and pathogenesis of the antiphospholipid syndrome | Q91454517 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | thrombosis | Q261327 |
| antiphospholipid syndrome | Q582207 | ||
| P304 | page(s) | 1916 | |
| P577 | publication date | 2019-04-23 | |
| P1433 | published in | Nature Communications | Q573880 |
| P1476 | title | Adenosine receptor agonism protects against NETosis and thrombosis in antiphospholipid syndrome | |
| P478 | volume | 10 |
| Q94940476 | Antiphospholipid Syndrome |
| Q110245879 | COVID-19 and antiphospholipid antibodies: A position statement and management guidance from AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) |
| Q104492300 | COVID-19 and autoimmune diseases |
| Q104559093 | COVID-19 in patients with systemic lupus erythematosus: lessons learned from the inflammatory disease |
| Q99604381 | Do free radical NETwork and oxidative stress disparities in African Americans enhance their vulnerability to SARS-CoV-2 infection and COVID-19 severity? |
| Q98177260 | Emerging role of NET inhibitors in cardiovascular diseases |
| Q90093923 | Extracellular DNA NET-Works With Dire Consequences for Health |
| Q97518173 | Harnessing adenosine A2A receptors as a strategy for suppressing the lung inflammation and thrombotic complications of COVID-19: Potential of pentoxifylline and dipyridamole |
| Q90090302 | Imaging of the immune system - towards a subcellular and molecular understanding |
| Q98181529 | Management of anticoagulant-refractory thrombotic antiphospholipid syndrome |
| Q92097321 | NETs spread ever wider in rheumatic diseases |
| Q91752666 | Preventing NETosis to reduce thrombosis |
Search more.